KR20200032162A - 항-bst-1 항체 및 시티딘 유사체를 포함하는 약학적 조합물 - Google Patents

항-bst-1 항체 및 시티딘 유사체를 포함하는 약학적 조합물 Download PDF

Info

Publication number
KR20200032162A
KR20200032162A KR1020207005030A KR20207005030A KR20200032162A KR 20200032162 A KR20200032162 A KR 20200032162A KR 1020207005030 A KR1020207005030 A KR 1020207005030A KR 20207005030 A KR20207005030 A KR 20207005030A KR 20200032162 A KR20200032162 A KR 20200032162A
Authority
KR
South Korea
Prior art keywords
antibody
bst1
cancer
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207005030A
Other languages
English (en)
Korean (ko)
Inventor
체칠리아 시모넬리
안드레아 펠라카니
모니카 비나스키
다니엘라 벨라로사
코라도 카리시
Original Assignee
베를린-케미 악티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베를린-케미 악티엔 게젤샤프트 filed Critical 베를린-케미 악티엔 게젤샤프트
Publication of KR20200032162A publication Critical patent/KR20200032162A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020207005030A 2017-07-21 2018-07-20 항-bst-1 항체 및 시티딘 유사체를 포함하는 약학적 조합물 Withdrawn KR20200032162A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies
GB1711785.4 2017-07-21
PCT/EP2018/069768 WO2019016371A1 (en) 2017-07-21 2018-07-20 PHARMACEUTICAL ASSOCIATIONS COMPRISING ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOG

Publications (1)

Publication Number Publication Date
KR20200032162A true KR20200032162A (ko) 2020-03-25

Family

ID=59771583

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005030A Withdrawn KR20200032162A (ko) 2017-07-21 2018-07-20 항-bst-1 항체 및 시티딘 유사체를 포함하는 약학적 조합물

Country Status (22)

Country Link
US (1) US20200231694A1 (enExample)
EP (1) EP3655033A1 (enExample)
JP (1) JP2020527594A (enExample)
KR (1) KR20200032162A (enExample)
CN (1) CN111132697A (enExample)
AR (1) AR112460A1 (enExample)
AU (1) AU2018303241A1 (enExample)
BR (1) BR112020001320A2 (enExample)
CA (1) CA3070264A1 (enExample)
CL (1) CL2020000175A1 (enExample)
CO (1) CO2020001792A2 (enExample)
EA (1) EA202090333A1 (enExample)
GB (1) GB201711785D0 (enExample)
IL (1) IL272096A (enExample)
MA (1) MA49627A (enExample)
MX (1) MX2020000752A (enExample)
PH (1) PH12020550024A1 (enExample)
SG (1) SG11202000390TA (enExample)
TW (1) TW201907952A (enExample)
UY (1) UY37815A (enExample)
WO (1) WO2019016371A1 (enExample)
ZA (1) ZA202000881B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
WO2013003625A2 (en) * 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Antibodies
GB201806084D0 (en) * 2018-04-13 2018-05-30 Berlin Chemie Ag Antibodies
CN118178645A (zh) * 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Also Published As

Publication number Publication date
CO2020001792A2 (es) 2020-07-31
BR112020001320A2 (pt) 2020-08-11
WO2019016371A1 (en) 2019-01-24
JP2020527594A (ja) 2020-09-10
GB201711785D0 (en) 2017-09-06
PH12020550024A1 (en) 2021-02-15
CN111132697A (zh) 2020-05-08
CA3070264A1 (en) 2019-01-24
UY37815A (es) 2019-02-28
EP3655033A1 (en) 2020-05-27
CL2020000175A1 (es) 2020-06-12
TW201907952A (zh) 2019-03-01
AR112460A1 (es) 2019-10-30
SG11202000390TA (en) 2020-02-27
US20200231694A1 (en) 2020-07-23
ZA202000881B (en) 2021-08-25
IL272096A (en) 2020-03-31
AU2018303241A1 (en) 2020-02-20
EA202090333A1 (ru) 2020-05-06
MA49627A (fr) 2020-05-27
MX2020000752A (es) 2020-08-17

Similar Documents

Publication Publication Date Title
KR101736076B1 (ko) 카드헤린-１７에 특이적인 항체
KR20130138802A (ko) 항체
US10982005B2 (en) Antibodies to bone marrow stromal antigen 1
KR102058185B1 (ko) Adp-리보실 시클라제 2에 대한 항체
US20210032360A1 (en) Antibodies against bst1 for preventing or treating myelodysplastic syndrome
US20120231004A1 (en) Antibodies
KR20200032162A (ko) 항-bst-1 항체 및 시티딘 유사체를 포함하는 약학적 조합물
HK1196138A (en) Antibodies to adp-ribosyl cyclase 2
HK1196138B (en) Antibodies to adp-ribosyl cyclase 2
RS56431B1 (sr) Antitela protiv adp-ribozil ciklaze 2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210706

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20220624